RnRMarketResearch.com analysts forecast the global restless legs syndrome (RLS) market to grow at a compound annual growth rate (CAGR) of 11.46% over the period 2014 to 2019. This is according to an about 80-page report the company published called Global Restless Legs Syndrome Market 2015-2019.
The analysis report draws attention towards the high unmet medical needs for patients suffering from RLS. An RnRMarketResearch.com analyst says, “The drugs marketed for restless legs syndrome (RLS) such as safinamide by Newron Pharmaceuticals appear to reduce the symptoms by novel mechanisms of action. Safinamide’s mechanism of action includes potent, selective, and reversible inhibition of MAO-B, without affecting MAO-A and dopamine uptake, thus enhancing dopaminergic function and inhibiting glutamate release. It reduces the degradation of dopamine, thus showing potential activity in the treatment of RLS. Similarly, Serina’s drug SER-214 involves a water-soluble polymer poly (2-alkyloxazoline)-based drug delivery technology. The drug can be connected to the polymer and delivered to target specific receptors.”
According to the report, the unknown etiology of the disease prevents the introduction of drugs that treat its exact cause. The currently marketed drugs offer only symptomatic relief. In addition, adverse effects such as nervous system disorders, which include sedation, headache, and dizziness; gastrointestinal disorders such as nausea, dry mouth, and flatulence; psychiatric disorders, including depression and decreased libido; metabolism and nutritional disorders, including weight gain and increased appetite; ear and labyrinth disorders resembling vertigo; and other general disorders such as fatigue, irritability, and peripheral edema are associated with the use of these drugs. The adverse effects caused by the drugs has created the need for unmet in the market. Any drug that can provide a complete cure with minimal side effects would experience widespread adoption in the market.
To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of RLS. The following companies are identified as the key players in the global market: Boehringer Ingelheim, GlaxoSmithKline, UCB, and XenoPort.
